Small Molecule Pharmaceutical

Globally, drugs must go through a thorough discovery and development process. Prior to clinical trials an investigator must submit an application to the appropriate regulatory body (Investigational New Drug (IND) in the US (FDA) and Japan (JPMA), CTA in Europe/EMEA), which requires certain tests be performed and the safety and potential hazard of that chemical assessed in what is termed the Preclinical or Pre-IND phase.

BioReliance offers an extensive portfolio of Toxicology testing and specializes in Genetic Toxicology and Transgenic Carcingenicity Assessment. We apply our significant experience and regulatory expertise to support your drug development needs.